Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 2, pp 115–120 | Cite as

A highly sensitive enzyme-linked immunosorbent assay for etoposide using β-d-galactosidase as a label

  • Tetsuya Saita
  • Kunio Fujiwara
  • Tsunehiro Kitagawa
  • Masato Mori
  • Katsumi Takata
Original Articles Etoposide, Galactosidase, ELISA


A highly sensitive enzyme-linked immunosorbent assay (ELISA) for etoposide (EP) was developed, which is capable of accurately measuring as little as 40 pg EP/ml. Anti-EP sera were obtained by immunizing rabbits with EP conjugated with mercaptosuccinyl bovine serum albumin (MS.BSA) usingN-[β-(4-diazophenyl)ethyl]maleimide (DPEM) as a heterobifuntional coupling agent. An enzyme marker was similarly prepared by coupling EP with β-d-galactosidase (β-Gal; EC via DPEM. This ELISA was specific for EP and showed a very slight cross-reactivity with its major metabolite,cis-hydroxy acid of EP (0.91%), but none with 4′-demethylepipodophyllotoxin and drugs commonly used with EP in combination chemotherapy for cancer treatment. The values for EP concentration detected by this assay were comparable with those detected by the highperformance liquid chromatography (HPLC) method. However, the ELISA was about 1,250 times more sensitive in detecting EP at lower concentrations. Using this assay, drug levels were easily determined in the blood and urine of rats for 7 h after i.v. administration of EP at a single dose of 3 mg/kg. Due to its sensitivity and specificity for EP, the ELISA should prove to be a valuable new tool for use in clinical pharmacological studies.


Ethyl Albumin Liquid Chromatography Bovine Serum Albumin Serum Albumin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aherne GW, Marks V (1982) A radioimmunoassay for VP16-213 in plasma. Cancer Chemother Pharmacol 7:117Google Scholar
  2. 2.
    Allen LM, Creaven PJ (1975) Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11:697Google Scholar
  3. 3.
    Colombo T, Broggini M, Torti L, Erba E, D'Incalci M (1982) Pharmacokinetics of VP16-213 in Lewis lung [carcinoma]-bearing mice. Cancer Chemother Pharmacol 7:127Google Scholar
  4. 4.
    Creaven PJ (1982) The clinical pharmacology of VM26 and VP16-213. Cancer Chemother Pharmacol 7:133Google Scholar
  5. 5.
    Creaven PJ, Allen LM (1975) PTG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 18:227Google Scholar
  6. 6.
    Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G (1982) Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 7:147Google Scholar
  7. 7.
    Farina P, Marzillo G, D'Incalci M (1981) High-performance liquid chromatography determination of 4′-demethylepipodophyllotoxin-9-(4,5-O-ethylidene)-β-d-glucopyranoside (VP-16-213) in human plasma. J Chromatogr 222:141Google Scholar
  8. 8.
    Fujiwara K, Saita T (1987) The use ofN-[β-(4-diazophenyl) ethyl]maleimide as a heterobifunctional gent in developing an enzyme immunoassay for neurotensin. Anal Biochem 161:157Google Scholar
  9. 9.
    Fujiwara K, Saikusa H, Yasuno M, Kitagawa T (1982) Enzyme immunoassay for the quantification of mitomycin C using β-galactosidase as a label. Cancer Res 42:1487Google Scholar
  10. 10.
    Fujiwara K, Saita T, Takenawa N, Matsumoto N, Kitagawa T (1988) Enzyme-linked immunosorbent assay for the quantification of actinomycin D using β-d-galactosidase as a label. Cancer Res 48:4843Google Scholar
  11. 11.
    Fujiwara K, Saita T, Kitagawa T (1988) The use ofN-[β-(4-diazophenyl)ethyl]maleimide as a coupling agent in the preparation of enzyme-antibody conjugates. J Immunol Methods 110:47Google Scholar
  12. 12.
    Ho DHW, Kanellopoulos KA, Yap HY, Casimir M, Savaraj N, Issell B, Benjamin RS, Bodey GP (1983) Clinical pharmacology of etoposide by radioimmunoassay. Proc Am Assoc Cancer Res 24:131Google Scholar
  13. 13.
    Issell BF (1982) The podophyllotoxin derivatives VP16-213 and VM26. Cancer Chemother Pharmacol 7:73Google Scholar
  14. 14.
    Issell BF, Crooke ST (1979) Etoposide (VP-16-213). Cancer Treat Rev 6:107Google Scholar
  15. 15.
    Kimura K, Yamada K, Niitani H (1985) A phase I clinical study of NK 171 (etoposide). Jpn J Cancer Chemother 12:851Google Scholar
  16. 16.
    Kimura K, Yamada K, Yoshida T (1986) Phase I study of NK171 (etoposide) on malignant lymphomas and acute leukemia. Jpn J Cancer Chemother 13:496Google Scholar
  17. 17.
    O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 312:692Google Scholar
  18. 18.
    Onoue K, Yagi Y, Pressman D (1964) Multiplicity of antibody protein in rabbit anti-p-azobenzenearsonate serum. J Immunol 92:173Google Scholar
  19. 19.
    Radice PA, Bunn PA, Ihde DC (1979) Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 63:1231Google Scholar
  20. 20.
    Sohda M, Fujiwara K, Saikusa H, Kitagawa T, Nakamura N, Hara K, Tone H (1985) Sensitive enzyme immunoassay for the quantification of aclacinomycin A using β-d-galactosidase as a label. Cancer Chemother Pharmacol 14:53Google Scholar
  21. 21.
    Strife RJ, Jardine I (1980) Analysis of the anticancer drugs VP16-213 and VM26 and their metabolites by high-performance liquid chromatography. J Chromatogr 182:211Google Scholar
  22. 22.
    Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputers. J Pharmacobiodyn 4:879Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Tetsuya Saita
    • 1
  • Kunio Fujiwara
    • 2
  • Tsunehiro Kitagawa
    • 2
  • Masato Mori
    • 1
  • Katsumi Takata
    • 1
  1. 1.Saga Medical SchoolFaculty of Hospital PharmacySagaJapan
  2. 2.Pharmaceutical SciencesNagasaki UniversityNagasakiJapan

Personalised recommendations